Abstract. Vitamin D deficiency has been found to be associated with a variety of cancers, including prostate, multiple myeloma, colorectal and breast cancer. Several studies have shown vitamin D levels to have an inverse relation with cancer mortality, while others have considered it a potential risk factor. Vitamin D is believed to influence cancer prevalence, risk and survival; hence the need to assess vitamin D levels in cancer. Although numerous studies have been conducted to demonstrate vitamin D deficiency as a risk factor for cancer, relatively few have studied its prevalence. Moreover, studies estimating prevalence differ from each other, with respect to study population, sample size, study design, definition of vitamin D deficiency used and method of vitamin D assessment (with most studies limited to one particular type of cancer with relatively small sample sizes). Therefore, we qualitatively reviewed the epidemiological evidence in the oncology literature on the prevalence of vitamin D deficiency and insufficiency as measured by serum vitamin D concentrations.
Introduction
Vitamin D is the prehormone important for maintaining normal calcium homeostasis and mineralization of the skeleton. Humans acquire vitamin D from exposure to sunlight, from their diet and from dietary supplements (1) . Vitamin D produced in the skin upon sun exposure or ingested from the diet is converted in the liver to 25- Although the biologically active form of vitamin D is 1,25(OH) 2 D, it is not considered a good biomarker due to its short half-life and tight homeostatic control (3) . Serum 25(OH) D is an excellent biomarker of vitamin D status, representing both cutaneous synthesis and dietary intake (4) . Adequate levels of vitamin D depend on age and therefore definitions of vitamin D deficiency vary. The appropriate thresholds for vitamin D deficiency are debated (4, 5) . The most widely accepted optimal level of serum 25(OH)D is 35-55 ng/ml. One study showed that for all health-related end points, the most advantageous serum levels for 25(OH)D appear to be at least 30 ng/ml, and for cancer prevention desirable levels are between 36 and 48 ng/ml (6) . The average older man and woman need intakes of at least 20-25 mcg (800-1,000 IU) per day of vitamin D to reach a serum 25(OH)D level of 30 ng/ml.
Brain, prostate, breast and colon tissues, among others, as well as immune cells, have a vitamin D receptor (VDR) and respond to 1,25(OH) 2 D, the active form of vitamin D. In addition, some of these tissues and cells express the enzyme 25-hydroxyvitamin D-1α-hydroxylase that converts 25(OH)D to 1,25(OH) 2 D (7, 8) . The active form of vitamin D has been shown to exert potent cell regulatory effects in cells other than those involved in calcium homeostasis. The effects are thought to be mediated through the VDR (9) . Binding of VDR by 1,25(OH) 2 D leads to multiple cellular effects, including induction of differentiation and apoptosis (10, 11) and inhibition of proliferation (12) , angiogenesis (13) and metastatic potential (14, 15) . Thus, vitamin D is believed to play an important role in the etiology and treatment of cancer.
Vitamin D deficiency has been found to be associated with a variety of cancers, including prostate (16, 17) , multiple myeloma, colorectal and breast cancer (18) . Certain studies have shown vitamin D levels to have an inverse relation with cancer mortality (19) (20) (21) (22) (23) (24) (25) , while others have considered it a potential risk factor. Higher vitamin D concentrations are associated with a 3-fold decreased risk for pancreatic cancer (highest vs. lowest quintile, >26.2 vs. <12.8 ng/ml) (26) . grant demonstrated that much of the geographic variation in cancer mortality rates in the US can be attributed to variations in solar UV-B radiation exposure. Clearly, improving vitamin D status appears vital to overall health, particularly in nonsummer months (27) . The evidence that higher 25(OH)D levels through increased sunlight exposure or dietary supplement intake inhibit colorectal carcinogenesis is substantial (28, 29) . The biologic evidence for an anti-cancer role of 25(OH)D is also strong for prostate cancer, but the epidemiologic data have not been supportive (30). The above data indicate that vitamin D influences cancer prevalence, risk and survival and hence the need to assess vitamin D levels in cancer.
Although numerous studies have been conducted to demonstrate vitamin D deficiency as a risk factor for cancer, relatively few have studied its prevalence. Most of the studies estimating prevalence have been limited to one particular type of cancer with relatively small sample sizes. Therefore, we qualitatively reviewed the epidemiological evidence in the literature on the prevalence of vitamin D deficiency and insufficiency as measured by serum 25(OH)D concentrations.
Search strategy and selection criteria
We performed a systematic search of the literature using the MeDLIne database (january 2000 through May 2010) to identify articles on the prevalence of serum vitamin D deficiency and insufficiency in cancer. We searched using the terms 'cancer/carcinoma' in combination with 'vitamin D deficiency', 'vitamin D insufficiency' and 'serum vitamin D/25(OH)D levels/concentration'. We also searched the bibliographies of the selected studies to identify relevant articles that we might have missed during the primary MeDLIne search. To be included in the review, a study must have been published in english, must have reported on data collected in humans with cancer, must have had measured serum vitamin D or serum 25(OH) D at single or multiple time points and must have utilized any of the following study designs (case-control, cohort, crosssectional, prospective, retrospective, case series, longitudinal, clinical trial). There were no restrictions according to age, ethnicity, type or stage of cancer. As we were interested in empirical reports that had investigated the prevalence of serum vitamin D deficiency and insufficiency in cancer, we did not include letters and meeting abstracts. All studies reviewed in this report are summarized in tables under separate headings and arranged chronologically by the year of publication.
Quality assessment
Although we did not formally rate the quality of reports we reviewed, we recorded and presented information on variables that may reflect the quality of reporting. The variables included years of data collection, study design, sample size, cancer type and stage, definition of vitamin D deficiency used, vitamin D assessment method, prevalence reported and supplementation recommended. Table I describes studies investigating the deficiency and  insufficiency of serum vitamin D in patients with breast cancer. The studies are arranged chronologically by the year of publication.
Studies on deficiency and insufficiency of serum vitamin D in breast cancer
nogues et al reported a prevalence of 85-92% of vitamin D deficiency in breast cancer patients. In their study, treatment with 16,000 IU of vitamin D every 2 weeks increased vitamin D plasma levels significantly in ~76.5% of subjects with baseline vitamin D deficiency (plasma levels <30 ng/ ml) over 3 months of follow-up. notably, in the few subjects that had baseline vitamin D levels ≥30 ng/ml, despite being prescribed vitamin D supplements (800 IU), their vitamin D levels did not increase significantly (31) . neuhouser et al assessed serum 25-25(OH)D status and its relationship to breast density in 426 breast cancer survivors. Most participants (76.8%) had vitamin D insufficiency or frank deficiency. no association of serum 25(OH)D with either breast density or breast dense area was observed. It was concluded that, despite the strong association of mammographic density with breast cancer risk, the mechanism is not likely to be mediated by vitamin D (32) . khan et al reported the safety and efficacy of vitamin D supplementation using 50,000 IU weekly on postmenopausal women. In their study, the prevalence of vitamin D deficiency was 63%. They also studied the effect of vitamin D-ss (standard supplementation) and vitamin D-HD (high dose) supplementation on serum 25(OH)D levels. Their results suggested that 50,000 IU of vitamin D3, when administered weekly to postmenopausal women starting adjuvant letrozole, resulted in clinically significant improvement in disability from joint symptoms (33) .
Crew et al reported a prevalence of 74% of vitamin D deficiency in breast cancer patients. They also observed that 400 IU of cholecalciferol daily for 1 year increased serum 25(OH)D levels only modestly, by <3 ng/ml, in only 15% of premenopausal women. Although the DRI for vitamin D in premenopausal women is only 200 IU daily, their study suggested that a dose of 400 IU daily was inadequate in breast cancer patients, even to maintain skeletal health, and was probably too low for meaningful anticancer effects (34 + /eR -and triple-negative. When assessing all of the breast cancer patients (91 total), it was found that 54 patients (62%) had baseline vitamin D levels in the deficiency range <32 ng/ml. Thirteen of the fifteen triplenegative breast cancer patients (87%) were found to be vitamin D deficient, prior to initiation of adjuvant therapy. These data may suggest that low vitamin D levels are more prevalent in triple-negative phenotype (35) . Waltman et al determined whether serum 25(OH)D concentrations were below normal (<30 ng/ml) in 29 breast cancer survivors receiving aromatase inhibitor therapy and whether musculoskeletal symptoms were related to these low vitamin D levels. The mean (SD) serum 25(OH)D level was 25.62 (4.93) ng/ml; 86% (n=25) had levels <0 ng/ml. The prevalence of vitamin D insufficiency in this sample was high despite the fact that their mean daily intake of vitamin D supplements was 665 IU and the mean time in the sun in the past week was reported as 39 min (36). Uk (40) stage III or IV, 75) D3 (40±21 pg/ ml) levels in breast cancer patients were lower than in women without cancer (53±23 pg/ml). The lack of a difference in the serum levels of 25(OH)D3 between women with and without breast cancer supports the probability that a low circulating concentration of 1,25(OH) 2 D3 in breast cancer patients is not attributed to 25(OH)D3 insufficiency (39) . palmieri et al prospectively measured circulating levels of 25(OH)D in 279 Caucasian women with invasive breast cancer, 204 women with early-stage disease and 75 women with locally advanced or metastatic disease. The results depicted that patients with early-stage breast cancer had significantly higher circulating levels of 25(OH)D (mean serum levels 22.8 ng/ml) than those with advanced disease (mean serum levels 18.4 ng/ml) (p<0.005) (40).
Studies on deficiency and insufficiency of serum vitamin D in colorectal cancer
Table II describes studies investigating the deficiency and insufficiency of serum vitamin D in patients with colorectal cancer (CRC). The studies are arranged chronologically by the year of publication.
Charalampopoulos et al determined the serum levels of vitamin D metabolites and parathyroid (pTH) in patients with colorectal cancer and found: i) no significant difference in the serum levels of 25(OH)D3 in each Dukes' clinical stage in cancer patients, ii) serum 1,25(OH) 2 D3 levels decreased with advanced cancer stages, and iii) serum levels of pTH showed a corresponding increase with advanced cancer stages. Low serum levels of 1,25(OH) 2 D3 on one hand, and increased levels of pTH in patients with colorectal cancer on the other, may be strongly related to the carcinogenetic process (41) . fakih et al carried out a study in the US comprising 315 patients with CRC, where 25-OH vitamin D status was dichotomized into two categories; 'very low' (<15 ng/ml) and 'low to normal' (>15 ng/ml). Twenty-nine out of 135 (21%) patients in stage 1 to 3 of CRC had serum levels of vitamin D in the 'very low' category along with 58 out of 180 (32%) patients in stage 4. It was recommended that patients with CRC, particularly those receiving chemotherapy, should be considered for aggressive vitamin D replacement strategies (42 Badros et al measured the prevalence of vitamin D deficiency in 100 multiple myeloma (MM) patients and showed that 40% had vitamin D deficiency, defined by serum 25(OH) D levels <14.4 ng/ml. Thirty-five percent had vitamin D insufficiency, defined by levels of 14.4-30 ng/ml. Only 25% had sufficient levels, defined as >30 ng/ml. They found no significant correlation between vitamin D status and MM activity (remission, relapsed or newly diagnosed), presence or absence of lytic bone disease and/or fractures or history of osteonecrosis of the jaw (50). everett et al conducted a study in patients at the Lynchburg Hematology-Oncology Clinic, where the number of patients tested for the first time from May to September were 86, 89, 72, 59 and 81, respectively. Of those tested, most had vitamin D levels <30 ng/ml (75.4, 84.1, 66.6, 69.3 and 63%, respectively). The study concluded that oncology clinicians must be aware of the potential negative effects of low vitamin D levels in their patient populations and should consider testing for and treating this deficiency or insufficiency in their practices (51). Reinhold et al measured the serum 25(OH)D concentration among subjects in a german polyclinic. In >50% of these 174 subjects, the 25(OH) D concentration was <20 ng/ml. In most subject groups, a seasonal decrease of 25(OH)D concentration was observed during the winter period. An age-related decrease in such a concentration was also observed in subjects with prostatic hyperplasia examined in the late summer/early autumn period and in female cancer subjects, at the exclusion of patients with breast cancer. In the latter patients, however, a positive correlation prevailed between age and 25(OH)D concentration (52) .
Hollender et al carried out a study in patients treated for gastric non-Hodgkin's lymphoma and found that of 33 patients out of 40 who met for follow-up examination after treatment, 17 patients had a partial gastrectomy (pg), 9 a total gastrectomy (Tg) and 7 patients were not operated on. The patients in the Tg group had significant weight loss. Moreover, the patients in the Tg group had a lower serum vitamin D than the other groups. They further concluded that when surgery is necessary, a pg should be performed when possible and that patients should receive dietary advice before leaving the hospital after surgery and possibly life-long iron, calcium, vitamin D, folate and vitamin B12 supplementation (53). Lammert et al measured serum 25(OH)D concentrations in 55 patients with neurofibromatosis 1 (nf1) and 58 healthy controls. The mean serum 25(OH)D concentration was 14.0 ng/ml among the patients with nf1 compared to 31.4 ng/ml among the healthy controls (p=0.0001). The strong correlation observed between nf1 patients and low serum vitamin D concentrations was unexpected. It is possible that patients with nf1 with multiple dermal neurofibromas are more likely to cover their skin and thus receive less sunlight than patients with nf1 who have fewer dermal tumors (54) . plant and Tisman demonstrated that out of 60 patients of different cancer types, when 25(OH) D insufficiency was defined as a serum level of <30 ng/ml, 43 (72%) patients were found to be insufficient. even at the lower definition of insufficiency, <20 ng/ml, 24 of 60 patients (40%) were insufficient. This study showed that the deficiency of vitamin D (72%) was prevalent among newly diagnosed patients with cancer and could play a role in cancer development and host response to tumor and therapy (55) .
Reichrath and Querings tested the hypothesis whether low serum levels of 25(OH)D may be a risk factor for the development of malignant melanoma. This study found that the mean (23.563 ng/ml) and median (24.591 ng/ml) 25(OH) D serum levels of these melanoma patients were in the normal range (20-50 ng/ml), indicating no relationship between serum levels of 25(OH)D and development of malignant melanoma (56). Tangpricha et al determined the prevalence of vitamin D deficiency in an outpatient cancer care clinic at Boston University Medical Center. A control group of healthy adults without cancer was recruited the previous year during the same months. Of the 56 patients with cancer, 27 (48%) had vitamin D deficiency (≤ 20 ng/ml), in comparison to only 6 (12%) of the 50 healthy control subjects (57).
Discussion
Vitamin D inadequacy constitutes a largely unrecognized epidemic in many populations worldwide (58) (59) (60) . It has been reported in healthy children (61) , adolescents (62) and adults (63, 64) . Lower vitamin D levels are associated with advancing age (65, 66) , female gender (67-69), history of diabetes (70), hypertension, greater body mass index (71) and a lower estimated glomerular filtration rate (72) . Vitamin D levels vary by region and are greater in summer than in winter months (73, 74) . Higher skin melanin levels increase the risk of vitamin D deficiency. Of late, there has been an increasing interest in the role of vitamin D in cancer etiology and outcomes and, as a result, several studies have reported the prevalence of vitamin D deficiency and insufficiency in patients with different types of cancer. However, the existing studies on this topic differ from each other with respect to study population, sample size, study design, definition of vitamin D deficiency used and method of vitamin D assessment. Therefore, we conducted a qualitative review of the existing literature with the goal of understanding the current status and providing insights on the directions for future research.
Twenty-seven studies were reviewed and most (n=12) were conducted prospectively to assess the 25(OH)D serum levels in different types of cancer patients. The other studies included retrospective (n=3), cross-sectional (n=2), case series Ten studies were conducted in breast cancer patients exclusively, three on colorectal, two on melanoma and one each on gastric lymphoma, multiple myeloma, neurofibroma, prostate, ovarian, thyroid and non-melanoma skin cancers, while the remaining five studies were based on a heterogenous group of cancer patients. While comparing the cut-off levels for definition of vitamin D deficiency, we found that the majority of the studies (n=11) used a threshold of <20 ng/ml. The other studies used different cut-offs ranging from 10 to 32 ng/ml. Most of the studies (n=10) measured the serum 25(OH)D levels using the radioimmunoassay, while some of the other studies used nichols Advantage assay kit (n=3), high-performance liquid chromatography (n=1), protein binding assay (n=2), competitive immunoluminometric direct assay (n=2) and chemiluminescent immunoassay (n=2). Many of these studies showed a prevalence of vitamin D deficiency >70% (31, (34) (35) (36) (37) 48, 51, 54) . A few studies (n=9) reported a prevalence rate between 40 and 70%, while the other studies (n=4) reported rates lower than 40%. Six studies reported only the mean serum vitamin D levels.
Some studies provided an estimate of vitamin D deficiency across stage of the disease, as well as season of vitamin D assessment. An inverse correlation between serum levels of vitamin D and carcinoma stage was demonstrated in three studies (40, 42, 43) . According to these studies, the serum levels of 25(OH)D were significantly higher in patients with early-stage cancer than in those with locally advanced or metastatic disease. An exception to this observation was one study on ovarian cancer patients (39) in which stage III and IV carcinoma patients had higher 25(OH)D serum levels than in stage I and II patients. A few studies also showed lower serum 25(OH)D levels in blood samples drawn during winter (31, 47, 52) depicting variations in the prevalence rate according to sun exposure. Some studies also reported results by gender. Badros et al reported an equal distribution of males and females with deficient serum 25(OH)D levels among patients with multiple myeloma (50) . Similarly, in colorectal cancer patients, fakih et al reported almost equal mean 25(OH) D levels among males and females (42) . Moreover, niv et al reported a higher prevalence rate of deficiency in females (31.6%) than in males (24.2%) among colorectal cancer patients (43) . In addition, a study by Crew et al also reported that vitamin D deficiency was slightly less common in white women (66%) compared to black (80%) and Hispanic (84%) women (34) .
Some studies also reported on supplementation recommendations to address vitamin D deficiency. Most studies suggested an aggressive vitamin D replacement strategy, including 50,000 IU weekly (n=3) or 50,000 IU twice a week (n=1) or 50,000 IU 1-3 times a week (n=1), while the others suggested a daily dose of vitamin D, including 2,000 IU (n=2) or 3,000 IU (n=1) orally. Thus, the recommended dosage by all studies ranged from 8,000 to 50,000 IU, one to three times a week for deficient patients. A few studies also suggested a maintenance dose regime ranging from 400 to 2,000 IU daily after the serum levels were raised to normal.
In conclusion, this review confirms a high prevalence of vitamin D deficiency in multiple cancer sites. Healthcare providers play important roles in disease prevention, health promotion and education. Since vitamin D deficiency is a widespread public health issue linked to cancer and other health risks, healthcare providers should not ignore this easily correctable condition. Therefore, evaluation of vitamin D levels and vitamin D supplementation for deficient individuals should be taken into consideration, while providing anticancer treatment. Optimizing vitamin D levels provides 'win-win' benefits of correcting vitamin D deficiency, promoting bone health and potentially reducing cancer risks. given the variation found in the studies in this review regarding the levels of 25(OH)D used to define deficiency, the method used to evaluate 25(OH)D, and even recommendations for supplementation for deficient individuals, additional research needs to be carried out to determine acceptable standards in these areas.
Since the prevalence of vitamin D deficiency appears to be high in multiple cancer sites, future research evaluating the impact of correcting and maintaining adequate vitamin D levels on survival outcomes and secondary prevention of cancer is essential.
